IPCA Q3 profit up by 24.15 percent


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ IPCA
The company’s board has declared an interim dividend of Rs 5 per share, Ipca Laboratories said. Shares of Ipca Laboratories were trading at Rs 1,270 per scrip on the BSE, up 1.78 per cent over the previous clos

 Ipca Laboratories on Wednesday reported a 24.15 per cent rise in consolidated net profit at Rs 197.54 crore for the quarter ended on December 31, 2019, on account of robust sales.The company had posted a net profit of Rs 159.11 crore for the corresponding period of previous fiscal, Ipca Laboratories said in a filing to the BSE.

Total income also rose to Rs 1,230.99 crore for the quarter under consideration as against Rs 1,019.48 crore in the year-ago period.

The company’s board has declared an interim dividend of Rs 5 per share, Ipca Laboratories said. Shares of Ipca Laboratories were trading at Rs 1,270 per scrip on the BSE, up 1.78 per cent over the previous close.

For more than 60 years, Ipca has been partnering healthcare globally in over 120 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments, one of the world's largest manufacturers and suppliers of over a dozen APIs.Produced right from the basic stage at manufacturing facilities inspected by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.

Ipca is also a therapy leader in India for anti-malarials with a market share of over 34% with a fast expanding presence in the international market as well. We also lead in DMARDs (Disease-Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. We have leading brands in 5 therapeutic areas, with 3 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS. Ipca was awarded as 'Among the 100 Best Companies to Work in India 2010' in a study conducted by Great Place to Work® - India in joint collaboration with The Economic Times.

Tags : #Ipca #Q3results #Riseinprofit

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026